Icotinib
Uses- Product Name
- Icotinib
- CAS No.
- 610798-31-7
- Chemical Name
- Icotinib
- Synonyms
- ConMana;N-(3-Ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine;CS-908;otinib;BP-1096;Icotinib;Lcotinib;BPI-2009;BPI-2009H;Icotinib BP-1096
- CBNumber
- CB82616025
- Molecular Formula
- C22H21N3O4
- Formula Weight
- 391.42
- MOL File
- 610798-31-7.mol
Icotinib Property
- Boiling point:
- 581℃
- Density
- 1.31
- Flash point:
- 305℃
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; ≥129.6 mg/mL in DMSO; ≥14.13 mg/mL in EtOH with ultrasonic
- form
- Powder
- pka
- 5.32±0.20(Predicted)
- color
- White to off-white
Safety
- HS Code
- 29339900
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P330Rinse mouth.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- AS117640
- Product name
- Icotinib
- Purity
- 98+%
- Packaging
- 1mg
- Price
- $52
- Updated
- 2021/12/16
- Product number
- CS-2017
- Product name
- Icotinib
- Purity
- 99.79%
- Packaging
- 5mg
- Price
- $70
- Updated
- 2021/12/16
- Product number
- CS-2017
- Product name
- Icotinib
- Purity
- 99.79%
- Packaging
- 10mg
- Price
- $100
- Updated
- 2021/12/16
- Product number
- AS117640
- Product name
- Icotinib
- Purity
- 98+%
- Packaging
- 5mg
- Price
- $136
- Updated
- 2021/12/16
- Product number
- 2468AH
- Product name
- Icotinib
- Packaging
- 5mg
- Price
- $153
- Updated
- 2021/12/16
Icotinib Chemical Properties,Usage,Production
Uses
Icotinib is a highly selective, 1st generation EGFR-TKI (epidermal growth factor receptor tyrosine kinase) inhibitor. The mutations of EGFR is associated with many kinds of cancers. Currently, Icotinib is under investigation for its treatment efficacy on some cancer such as non-small cell lung cancer. Icotinib take effects through binding reversibly to the ATP binding site of the EGFR protein, further preventing completion of the signal transduction cascade.
Description
Icotinib is also known as ConMana. It is a highly selective, first-generation inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TKI), whose mutation and overexpression is involved in many kinds of cancer. Icotinib is a quinazoline derivative that binds reversibly to the ATP binding site of the EGFR protein, being capable of blocking the signal transduction cascade. It is currently under investigation for its treatment efficacy on the EGFR+ Non-small cell lung cancer.
Uses
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with IC50 of 5 nM.
Indications
Icotinib (Conmana?, BetaPharma), an EGFR inhibitor, was approved by the China State FDA in 2011 for the treatment of NSCLC. Icotinib resembles erlotinib in possessing the N-(3-ethylnylphenyl) quinazolin-4-amine core scaffold of erlotinib that binds to the EGFR ATP pocket. An adjacent hydrophobic group was also retained while the solvent exposed two 2-methoxyethyoxysubstituents at the 6- and 7-positions of the quinazoline core were cyclized to afford the tetraoxacyclododecene moiety of icotinib. Efficacy and safety of icotinib as first-line therapy in patients has been evaluated for advanced NSCLC in recent clinical studies.
General Description
Class: receptor tyrosine kinase
Treatment: NSCLC
Oral bioavailability = 52%
Elimination half-life = 5.5 h
References
Tan, F., et al. "Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. " Lung Cancer76.2(2012):177-82.
Shi, Y., et al. "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial." Lancet Oncology 14.10(2013):953-61.
Sun, Y., Y. Shi, and L. Zhang. "A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)."Journal of Thoracic Oncology 29.15(2011):-.
https://en.wikipedia.org/wiki/Icotinib
Icotinib Preparation Products And Raw materials
Raw materials
Preparation Products
Icotinib Suppliers
- Tel
- --
- Fax
- --
- sales@ajchem.in
- Country
- India
- ProdList
- 6100
- Advantage
- 58
View Lastest Price from Icotinib manufacturers
- Product
- Icotinib 610798-31-7
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-10
- Product
- Icotinib 610798-31-7
- Price
- US $15.00-10.00/KG
- Min. Order
- 1KG
- Purity
- 99%+ HPLC
- Supply Ability
- Monthly supply of 1 ton
- Release date
- 2021-07-09
- Product
- Icotinib 610798-31-7
- Price
- US $1.00/KG
- Min. Order
- 1KG
- Purity
- 95%
- Supply Ability
- 500kg
- Release date
- 2018-08-19